Commentary|Articles|July 30, 2014

Special Reports

  • NSCLC (Issue 3)
  • Volume 3
  • Issue 1

Cabozantinib Plus Erlotinib for Advanced EGFR-Mutant NSCLC

Karen L. Reckamp, MD, discusses a phase II, single-arm study of cabozantinib plus erlotinib for the treatment of patients with advanced EGFR-mutant non-small cell lung cancer (NSCLC).

Karen L. Reckamp, MD, co-director, Lung Cancer and Thoracic Oncology Program, associate professor, City of Hope, discusses a phase II, single-arm study of cabozantinib plus erlotinib for the treatment of patients with advanced EGFR-mutant non-small cell lung cancer (NSCLC).

Learn more about the combination of cabozantinib and erlotinib for NSCLC > >


Latest CME